MEI Pharma Launches $100M Litecoin Treasury, Shares Jump 50%
MEI Pharma, a Nasdaq-listed biotech firm, has launched a $100 million Litecoin treasury plan to diversify its assets. The strategy, led by Titan Partners and GSR, is backed by the Litecoin Foundation, which also took a strategic equity stake in MEI Pharma. Litecoin creator Charlie Lee joins MEI Pharma’s board to drive institutional Litecoin adoption, highlighting the low fees, fast settlement and proven payment use cases of Litecoin.
The announcement drove MEI Pharma’s shares up over 50% at market open and marks one of the largest corporate Litecoin treasury strategies to date. This move follows Thumzup Media’s $250 million crypto asset plan, underscoring growing institutional interest in Litecoin and other digital currencies. Traders will monitor the Litecoin treasury plan’s impact on LTC demand, market liquidity and MEI Pharma’s stock volatility.
Bullish
This news is bullish for LTC because a $100 million corporate treasury allocation demonstrates strong institutional confidence and drives demand. Charlie Lee’s board appointment and the Litecoin Foundation’s equity stake add credibility, while the share price jump highlights market enthusiasm. Large-scale corporate adoption often leads to increased network usage and reduced sell pressure, supporting both short-term price spikes and long-term value growth.